Last updated: 2026-09-08 22:19:20. Prices reflect the latest after-hours trading data. Stock price data is sourced from Massive.
Alpha Cognition Inc. (ACOG) operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector and is listed on NASDAQ. The stock is currently priced at $9,63, with a market capitalization of $207,33M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $4,50 to $10,14. This page covers its latest market performance, valuation, price trends and company information.
$207,33M | |
$9,31 | |
$11,54 | |
$3,75 | |
$9,52 | |
83,97K | |
105,65K | |
-- | |
$10,14 | |
$4,50 | |
-- | |
-- |
Alpha Cognition Inc. (ACOG) is trading at $9,75 in after-hours trading as of 2026-09-08 21:58:00, up 2,42% ($0,23) from the regular-session close of $9,52.
After-hours trading shows how investors are pricing ACOG after the regular session closes. The current after-hours price is above the regular-session close, indicating positive after-hours sentiment.
Over the past seven days, Alpha Cognition Inc. (ACOG) moved from $9,74 to $9,63, representing a decline of 1,12% ($0,11).
The stock traded between $8,92 and $10,01 during the period. The latest price is near the middle of the 7-day range, indicating moderate downward.
The average daily volume was 124,58 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 90,9%
ACOG is currently trading at $9,63, placing it 90,9% of the way from its 52-week low of $4,50 to its 52-week high of $10,14. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Alpha Cognition Inc is a biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimers disease, for which there are limited or no treatment options. The Companies current focus is on the commercial manufacturing and sales of ZUNVEYL oral tablet formulation. The Companies commercial development program for ZUNVEYL is focused on building a long-term care commercial team that can focus on providing key points of differentiation, exploiting key issues with existing Acetylcholinesterase inhibitors treatments, and seeking potential licensing partners for other additional indications and new formulations.
| Industry | BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) |
| Employees | 71 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Alpha Cognition Inc. (ACOG) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.